Skip to main content
. Author manuscript; available in PMC: 2020 Jul 30.
Published in final edited form as: N Engl J Med. 2020 Jul 30;383(5):426–439. doi: 10.1056/NEJMoa1908380

Figure 2 a-c.

Figure 2 a-c

Kaplan-Meier Plots for the Primary and Secondary Efficacy Endpoints in the Per-Protocol Population

Panel 2a: Time to RSV Medically-significant Lower Respiratory Tract Infection

Panel 2b: Time to RSV Lower Respiratory Tract Infection with Severe Hypoxemia

Panel 2c: Time to RSV Lower Respiratory Tract Infection with Hospitalization